Ceragenix Pharmaceuticals, headquartered in Denver, USA, will provide data at the Medtech Insight conference in Paris on April 28-29 to demonstrate that antibacterial polyurethane-coated catheters can prevent infection.
Ceragenix used its proprietary CeraShield material for experiments comparing the in vivo antibacterial effect of CeraShield silicone coated catheters with commercial silver coated catheters or using nitrofurazone according to the daily average amount of E. coli. The polyurethane CeraShield material contains CSA-13, a Ceragenin chemical that is multidrug resistant and resistant to Gram-positive and Gram-negative bacteria. Experiments have shown that the CeraShield coated airway prevents the bacterial expansion and the formation of biofilm for 21 days in the highly inoculated P. aeruginosa state. The silver-coated urinary catheter can reduce the risk of bacterial urine in men for about 5 days, but it cannot be used for a long time.
Catheters are prone to cause urinary tract infections and E. coli is the most common cause of such infections. Therefore, the annual cost of hospital admissions in the United States exceeds $450 million. It is estimated that more than 900,000 UTIs use urinary catheters per year in the United States.
Steve Porter, Ceragenix’s chairman and chief executive officer, said: “The healthcare center has developed a keen interest in innovative technologies to reduce the incidence of such infections, so it has recently decided to no longer pay for hospital-acquired urinary tract infections. The company believes CeraShield is better than current treatments. Technology has greater advantages. We look forward to conducting more necessary experiments to advance the technology into the market as soon as possible.â€
Ceragenix used its proprietary CeraShield material for experiments comparing the in vivo antibacterial effect of CeraShield silicone coated catheters with commercial silver coated catheters or using nitrofurazone according to the daily average amount of E. coli. The polyurethane CeraShield material contains CSA-13, a Ceragenin chemical that is multidrug resistant and resistant to Gram-positive and Gram-negative bacteria. Experiments have shown that the CeraShield coated airway prevents the bacterial expansion and the formation of biofilm for 21 days in the highly inoculated P. aeruginosa state. The silver-coated urinary catheter can reduce the risk of bacterial urine in men for about 5 days, but it cannot be used for a long time.
Catheters are prone to cause urinary tract infections and E. coli is the most common cause of such infections. Therefore, the annual cost of hospital admissions in the United States exceeds $450 million. It is estimated that more than 900,000 UTIs use urinary catheters per year in the United States.
Steve Porter, Ceragenix’s chairman and chief executive officer, said: “The healthcare center has developed a keen interest in innovative technologies to reduce the incidence of such infections, so it has recently decided to no longer pay for hospital-acquired urinary tract infections. The company believes CeraShield is better than current treatments. Technology has greater advantages. We look forward to conducting more necessary experiments to advance the technology into the market as soon as possible.â€